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Local production of prostaglandins by osteoblasts may be important in controlling the bone resorbing 
activity of some hormones which have receptors on osteoblasts. We have demonstrated that osteoblast-like 
cells derived from human bone can incorporate [14C]arachidonic acid into phospholipids and synthesise 
immunoreactive PGE. Parathyroid hormone increases both the release of incorporated arachidonic acid 
and the synthesis of PGE. This is the first demonstration of modulation of bone cell prostaglandin 
synthesis by a bone resorbing hormone. 
Human bone cell Prostaglandin PTH 1,2SDihydroxyvitamin D3 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Both parathyroid hormone (PTH) and 1,25-di- 
hydroxycholecalciferol [1,25(0H)~D~] stimulate 
bone resorption in organ culture. However the 
mechanisms involved in this process remain un- 
clear. It has been suggested that the activity of 
some bone resorbing agents may be mediated by 
the osteoblast [I]. One hypothesis is that the 
osteoblast is stimulated to release factors which 
then act directly on the osteoclast. One group of 
such factors could be prostaglandins, some of 
which stimulate bone resorption and can be syn- 
thesised by osteoblasts in vitro [2,3]. We have 
developed a system for culturing non-transformed 
cells from adult human bone. These cells display 
the characteristics expected of osteoblasts and res- 
pond to a wide range of hormones and drugs [4]. 
We have investigated the incorporation and release 
of [‘4C]arachidonic acid, the production of 
immunoreactive prostaglandin E (PGE) by human 
bone cells and the effects of PTH and 1,25(0H)~D~ 
on these activities. 
2.1. Human bone ceil culture 
Specimens of human trabecular bone were ex- 
tensively washed in phosphate-buffered saline 
(PBS) and dissected into fragments 0.3-0.5 cm in 
diameter. Explants were plated out into 9 cm tissue 
culture dishes (5-8 explants/dish) and cultured in 
Eagles minimum essential medium, containing 
10% fetal calf serum (EMEM + 10% FCS), and 
I % penicillin/streptomycin solution (10000 
units/ml). All cultures were maintained at 37°C in 
a humidified atmosphere of 95% sir/5% COZ. 
Cells migrating from the explants formed a con- 
fluent monolayer after 3-5 weeks. All cell cultures 
used in these experiments ynthesised osteocalcin 
in response to 1,25(OH)~D3 (5 x 10m9 M), and all 
experiments were conducted at first subculture. 
2.2. Measurement of prostaglandins 
Cells were passaged using 0.5% trypsin/0.02% 
EDTA into 3.5 or 1.6 cm multiwells at varying cell 
densities (fig.1) and allowed to settle for 24 h. 
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After 24 h incubation with or without PTH the 
medium was assayed for PGE content by radioim- 
munoassay using antiserum to PGEz which also 
recognised PGEi. Cross-reactivities with 6-keto 
PGFi,, PGFh, TxBz and PGDz were all less than 
0.05% at 50% displacement of the [3H]PGE~ 
tracer. In some wells bovine PTH (0.1-B. 1 III/ml) 
or 1,25(OH)~D3 (10-10-10-8 M) was added. 
Neither of these agents cross-reacted with the 
antibody. 
2.3. Incorporation and release of [‘4C]arachidonic 
acid 
2.3.1. Incorporation 
Cells were passaged into 3.5 cm multiwells (10’ 
cells/well) and allowed to settle for 24 h. The cells 
were incubated in EMEM + 0.5% bovine serum 
albumin (BSA) containing 1.6 ,&/ml 
[14C]arachidonic acid (58 mCi/mmol) for 4 h. 
Cells were removed from the plate with tryp- 
sin/EDTA and frozen to -20°C. Phospholipids 
were extracted and separated by thin-layer 
chromatography (TLC) as in [5]. Radioactivity 
areas were visualised by autoradiography and the 
relative amounts of radioactivity in each fraction 
were determined by densitometry using an LKB 
Ultroscan laser densitometer. A standard quantity 
of each phospholipid was run as standard. 
2.3.2. Release 
Cells were passaged into 9 cm tissue culture 
plates (lo6 cells/plate) and after 24 h were in- 
cubated in EMEM + 0.5% BSA containing 
1.6 &i/ml [14C]arachidonic acid for 4 h. This 
medium was removed and stored and the cells 
washed 4 times with PBS to remove any residual 
unincorporated radioactivity. Cells were then in- 
cubated in 5 ml BGJ medium without serum, con- 
taining in some cases PTH (l-84) (2.0 III/ml). 
Radioactivity released was assessed by liquid scin- 
tillation counting. 
2.4. Materials 
Penicillin/streptomycin solution, 0.5% tryp- 
sin/0.02% EDTA, EMEM, FCS and BGJ medium 
were purchased from Gibco (Paisley, Scotland). 
All tissue culture vessels purchased from Falcon 
(Oxford). [3H]PGEz and [r4C]arachidonic acid 
were purchased from Amersham International plc. 
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Solvents and plates for TLC were purchased from 
E. Merck (Darmstadt). Purified bovine PTH 
(l-84) was obtained from National Institutes for 
Biological Standards, Mill Hill, England. 
1,25(OH)zD3 was a gift from Hoffman La Roche. 
Antiserum to PGEz was a kind gift from R.A. 
Forder, ICI Pharmaceuticals. 
3. RESULTS AND DISCUSSION 
Results from two separate bone cell cultures in- 
dicated that, after a 4 h incubation with 
[14C]arachidonic acid, most of the label is incor- 
porated into the neutral lipid fraction (table 1). 
However appreciable amounts may also be found 
in the phosphatidylcholine (PC) and 
phosphatidylinositol (PI) fractions (table 1). Basal 
release of previously incorporated arachidonic acid 
represented 9.5% of the incorporated radioactivi- 
ty. Addition of PTH (2.0 IU/ml) stimulated this 
release to 16.3%. PTH-stimulated release of 
arachidonic acid was inhibited by 1,25(OH)~D3 
(10e8 M) to 7.2% of incorporated radioactivity. 
These results demonstrate that cells derived 
from human bone can incorporate [14C]ara- 
chidonic acid into phospholipids from which it 
may be released, presumably by the action of 
phospholipase AZ. This enzyme is activated by 
Table 1 
Incorporation of [14C]arachidonic acid into the lipid 
fractions of cells derived from human bone 
[ 14C]Arachidonic acid 
(070) 
Culture 1 Culture 2 
TG 55.3 53.0 
PC 30.8 27.0 
PE 2.2 2.1 
PI 8.9 10.8 
PS 1 1.2 
Results show the percentage of a 2000 cpm aliquot of the 
cell layer radioactivity incorporated into the triglyceride 
and each of the major phospholipid fractions after TLC 
(see section 2). Culture 1, normal trabecular bone/2 yr 
old; culture 2, normal trabecular bone/l9 yr old. TG, 
triglyceride; phosphatidylcholine; 
phosphatidyletha%kmine; PI, phosphatidylinosi::: 
PS, phosphatidylserine 
Volume 169, number 1 FEBS LETTERS April 1984 
agents which increase influx of calcium. The 
presence of calcium-dependent phospholipase AZ 
may explain the increased release of arachidonic 
acid in response to PTH since this hormone 
stimulates the influx of calcium into rodent bone 
cells [6]. The liberated arachidonic acid may then 
act as substrate for the cycle-oxygenase and lipo- 
xygenase enzymes. Thus PTH is able to stimulate 
the production of immunoreactive PGE by cells 
derived from human bone. 
Production of PGE by human bone cells was 
stimulated by bovine PTH 1-84 in 6 separate ex- 
periments. Data from 3 of these are presented in 
fig.1. In contrast, lo-* M 1,25(OH)zD3 decreased 
basal production of PGE. Data from 3 separate x- 
periments are shown in fig.1. Prostaglandins are 
potent stimulators of bone resorption in vitro [7]. 
Previous studies have demonstrated that 
osteoblast-like cells are capable of synthesising 
prostaglandins [2,3] and also that several bone 
resorbing agents including epidermal growth fac- 
tor (EGF) [8] and platelet derived growth factor 
PTH W/ml) 
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Fig.1. Synthesis of prostaglandins by various human 
bone cell cultures. (0) Normal bone, bovine PTH 
(l-84), 1 x lo4 cells/cm2, 5% FCS; (A) normal bone, 
bovine PTH (l-84), 0.25 x lo4 cells/cm2, 10% FCS; (m) 
normal bone, bovine PTH (l-84), 0.15 x lo4 cells/cm2, 
10% FCS; (0) normal bone, 1,25(OH)zD3, 0.5 x lo4 
cells/cm2, 1% FCS; (A) normal bone, 1,25(OH)zDr, 
0.2 X lo4 cells/cm2, 5% FCS; (0) normal bone, 
1,25(OH)zDs, 4 x 104 cells/cm2, 10% FCS. All points 
represent the percentage difference from control, as 
assessed by the means + SE of 6 separate incubations. 
Values significantly different from control: * p < 0.05, 
*** p < 0.001. 
(PDGF) [9] require the production of prostaglan- 
dins by bone in organ culture to mediate their ac- 
tivity. This has led to the concept of mediation of 
bone resorbing activity by osteoblastic production 
of prostaglandins. 
Osteoblasts have receptors for PTH [lo], and it 
has been proposed that the bone resorbing activity 
of this hormone may be modulated through the 
osteoblast. This hypothesis is consistent with our 
present demonstration that PTH stimulates pro- 
duction of PGE by human bone cells in culture. 
The concentrations of PTH capable of stimulating 
prostaglandin synthesis (0.9 III/ml) are within the 
range used in previous bone resorption studies 
[l 11. This is the first demonstration that produc- 
tion of prostaglandins by osteoblast-like cells may 
be affected by hormonal factors. 
Previous investigation of PTH-stimulated bone 
resorption has produced conflicting data on the ef- 
fect of inhibition of cycle-oxygenase. Authors in 
[12] demonstrated a partial inhibition of bone 
resorption in the mouse calvarial system using 
aspirin whereas those in [13] did not show any ef- 
fect of indomethacin. However, it is now recogni- 
sed that the cycle-oxygenases of different tissues 
vary in sensitivity to inhibitors such as in- 
domethacin [ 141. 
Preliminary results from separation of 
[14C]arachidonic acid metabolites by TLC suggest 
that human bone cells possess both cyclo- 
oxygenase and lipoxygenase pathways and are 
capable of metabolising arachidonic acid into a 
number of identifiable products and one uniden- 
tified metabolite. The fact that not all bone resorb- 
ing agents are likely to mediate their activity via in- 
creased osteoblastic production of prostaglandins 
is highlighted by the inhibitory effect of 
1,25(OH)zDj on synthesis of PGE. 
In conclusion we have obtained evidence that 
PTH increases, whereas 1,25(OH)~D3 decreases, 
the production of prostaglandins by cells derived 
from human bone. This effect of PTH may 
mediate some or all of its bone resorbing activity. 
However the opposing effects of these agents on 
the synthesis of prostaglandins may also be impor- 
tant in the regulation of osteoblastic function. 
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